As of September, 2012, the patient has been on imatinib therapy for 131 months and remains progression free.<h4>Conclusions</h4>The results of this case report demonstrated that a patient with metastatic KIT+ GIST who was initially intolerant to imatinib maintained, and responded to imatinib therapy after treatment of an imatinib-associated adverse effect. This evidence concerns the gene KIT and gastrointestinal stromal tumor.